Elevance Health, INC 8-K filings

Elevance Health reported strong second quarter 2026 results, exceeding expectations and leading to an increase in full-year guidance for both earnings per share and operating cash flow.

Elevance Health reaffirms its 2026 earnings per diluted share guidance and benefit expense ratio guidance during investor meetings.

Elevance Health's annual shareholder meeting saw the election of directors, approval of executive compensation, and ratification of its auditor, with one shareholder proposal failing to pass.

Elevance Health reported strong first quarter 2026 results, exceeding expectations and leading to an increase in full-year adjusted EPS guidance.

Elevance Health, Inc. announced that the Centers for Medicare & Medicaid Services intends to impose sanctions suspending new Medicare Advantage enrollments and certain communications due to past data submission noncompliance.

Elevance Health announced key executive leadership changes and reaffirmed its full-year 2026 financial guidance, including adjusted earnings of at least $25.50 per diluted share.

Elevance Health announced its fourth quarter and full year 2025 results, reporting robust revenue growth and shareholder returns while setting a cautious outlook for 2026.

Elevance Health announced the election of Amy W. Schulman, a recognized healthcare executive and investor, as an independent director, effective January 12, 2026.

Elevance Health, Inc. reaffirms its full-year 2025 shareholders earnings guidance of approximately $24.70 per diluted share and a benefit expense ratio of approximately 90.0%.

Elevance Health reports third quarter 2025 results in line with expectations, driven by revenue growth and strategic investments despite Medicaid membership losses.

Elevance Health finalized the sale of $3 billion in notes to repay debt and for general corporate purposes.

Elevance Health, Inc. reaffirmed its full-year 2025 earnings guidance of approximately $24.10 per diluted share and an adjusted $30.00 per diluted share.

Elevance Health, Inc. announced the election of Steven H. Collis, former President and CEO of Cencora, as an independent director to its Board, effective August 1, 2025.

A major health insurer reported increased second-quarter revenue but revised its full-year adjusted diluted EPS guidance downward due to elevated medical cost trends in ACA and Medicaid.

Elevance Health, Inc. announced it will reaffirm its full-year 2025 shareholders' earnings guidance of $28.30 to $29.00 per diluted share, and adjusted earnings of $34.15 to $34.85 per diluted share, along with its benefit expense ratio, during upcoming investor meetings.

Elevance Health's annual shareholder meeting resulted in the election of directors, approval of executive compensation, ratification of Ernst & Young LLP as the independent accounting firm, and rejection of a shareholder proposal on Diversity, Equity, and Inclusion efforts.

Elevance Health reported a 15.4% increase in first quarter 2025 operating revenue, reaching $48.8 billion, and reaffirmed its full year adjusted diluted EPS guidance of $34.15 to $34.85.

Elevance Health expects to report a strong first quarter in 2025 and reaffirms its full-year adjusted net income guidance.

Elevance Health reaffirms its full-year 2025 earnings guidance and medical enrollment expectations.

Elevance Health reported a 6% increase in Q4 operating revenue to $45.0 billion, but experienced a decrease in net income and provided a 2025 outlook with projected EPS growth.

Elevance Health successfully closed a $5.2 billion debt offering, issuing multiple tranches of notes with varying maturities and interest rates.

Elevance Health's third-quarter results show revenue growth offset by Medicaid membership losses and increased benefit expenses, leading to a revised full-year earnings outlook.

Elevance Health's second quarter 2024 results show a slight decrease in operating revenue, offset by growth in other areas, and a 26% increase in diluted EPS.

Elevance Health reaffirms its full-year 2024 net income guidance, projecting over $37.20 per diluted share on an adjusted basis.

Elevance Health has successfully closed a $2.6 billion debt offering, issuing notes due in 2029, 2034, and 2054 to fund working capital, acquisitions, debt repayment, and share repurchases.

Elevance Health held its annual shareholder meeting on May 15, 2024, where directors were elected, executive compensation was approved, and the appointment of Ernst & Young LLP was ratified.

Elevance Health's first quarter 2024 results show a 15.5% increase in diluted EPS and a raised full-year earnings outlook, driven by strategic initiatives and growth in Carelon.

Elevance Health reaffirms its 2024 net income guidance and reports a positive update to its Medicare Advantage Star Ratings, resulting in an estimated $190 million revenue benefit.

Elevance Health's Audit Committee has declared a quarterly cash dividend of $1.63 per share, payable on March 22, 2024, to shareholders of record as of March 8, 2024.

Elevance Health reported a 9.3% increase in full-year operating revenue for 2023 and projects continued growth in 2024.